In a blog post today, AHA Executive Vice President Tom Nickels takes issue with a comparing hospital prices to drug prices. 鈥淐omparing hospital prices to drug prices is absurd,鈥 Nickels writes. 鈥淎nd although the article claims to be about prices, the chart actually shows National Health Expenditure spending numbers, not prices. Despite that, hospital spending has grown at a slower rate than drug spending over the time period displayed in the chart. And as a percentage of the NHE, hospital care actually declined from 42.7% in 1980 to 34% in 2016, compared to retail prescription drug spending, which doubled as a share of total national health expenditures. 鈥 Hospital prices have also grown more slowly than drug prices, despite rising input costs. Hospital price growth as measured by the Producer Price Index, has remained under 2% for each of the last four years. Even before that, since 2008, hospital prices had an average annual growth rate of 2%. In comparison, the overall price of medical care had an average annual growth rate of 3%, while drug prices had a significantly higher average annual growth rate of 5.6% for that same time period.鈥

Related News Articles

Headline
The AHA Aug. 7 filed an amicus brief in the Supreme Court in defense of states鈥 affidavit of merit requirements in federal court, which require plaintiffs to鈥
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the鈥
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug鈥
Headline
The American Society for Health Care Engineering July 28 announced the recipients of its annual member awards during the 2025 Health Care Facilities Innovation鈥
Headline
The American Society for Health Care Engineering July 1 announced 87 health care facilities as winners of the 2025 Energy to Care Sustainability Champions鈥
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state鈥檚鈥